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Abstract
Background: In the last decade, the inhibition of protein-protein interactions (PPIs) has emerged from both academic and
private research as a new way to modulate the activity of proteins. Inhibitors of these original interactions are certainly the
next generation of highly innovative drugs that will reach the market in the next decade. However, in silico design of such
compounds still remains challenging.
Methodology/Principal Findings: Here we describe this particular PPI chemical space through the presentation of 2P2IDB,a
hand-curated database dedicated to the structure of PPIs with known inhibitors. We have analyzed protein/protein and
protein/inhibitor interfaces in terms of geometrical parameters, atom and residue properties, buried accessible surface area
and other biophysical parameters. The interfaces found in 2P2IDB were then compared to those of representative datasets of
heterodimeric complexes. We propose a new classification of PPIs with known inhibitors into two classes depending on the
number of segments present at the interface and corresponding to either a single secondary structure element or to a more
globular interacting domain. 2P2IDB complexes share global shape properties with standard transient heterodimer
complexes, but their accessible surface areas are significantly smaller. No major conformational changes are seen between
the different states of the proteins. The interfaces are more hydrophobic than general PPI’s interfaces, with less charged
residues and more non-polar atoms. Finally, fifty percent of the complexes in the 2P2IDB dataset possess more hydrogen
bonds than typical protein-protein complexes. Potential areas of study for the future are proposed, which include a new
classification system consisting of specific families and the identification of PPI targets with high druggability potential
based on key descriptors of the interaction.
Conclusions: 2P2I database stores structural information about PPIs with known inhibitors and provides a useful tool for
biologists to assess the potential druggability of their interfaces. The database can be accessed at http://2p2idb.cnrs-mrs.fr.
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Introduction
In the last decade, the inhibition of protein-protein interactions
(PPIs) has emerged from both academic and private research as a
new way to modulate the activity of proteins (for an in depth
review see Roche and Morelli [1]). Based on this new focus, it is
now more and more commonly accepted that protein-protein
complexes are an important class of therapeutic targets [2]. PPIs
can be involved in a network of complex interactions that play a
central role in various cellular events. These interactions control
processes involved in both normal and pathological pathways,
which include signal transduction, cell adhesion, cellular prolifer-
ation, growth, differentiation, viral self-assembly, programmed cell
death and cytoskeleton structure (for a review refer to [3]).
In parallel to this new field, large scale genomics and proteomics
programs have permitted the identification of entire protein
networks interactomes at the cellular level. These programs have
led to major breakthroughs in understanding biological pathways,
host-pathogen interactions and cancer development. With the
growing tools of small molecules, the modulation of these networks
of interactions represents a promising therapeutic strategy.
Protein-protein interaction inhibitors (2P2Is) are certainly the
next generation of highly innovative drugs that will reach the
market in the next decade.
As a consequence of this enthusiasm, the exponential increase of
published biomedical literature on PPIs and their inhibition has
prompted the development of internet services and databases that
help scientists to manage the available information. There is now a
growing number of structural databases dedicated to protein-
protein interactions [4–7]. A large variety of these PPIs databases
depict protein-protein interactions at a structural level (for a
summary of these available databases refer to [1]), but they focus
only on this particular interface without taking into account the
potential inhibitors related to one of the two partners. In a recent
survey, Higuerueolo et al. analyzed the atomic interactions and
profile of small molecules disrupting PPIs in the TIMBAL database,
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to drug-like databases[4].Severalotherstudies have alsofocused on
subsets of small molecules that disrupt PPIs [5,6,7,8]. However,
none of them have focused on both the protein-protein structural
information available and the known inhibitors within the interface.
We describe here a chemical space, 2P2IDB, which is a hand-
curated database dedicated to the structure of Protein-Protein
complexes with known inhibitors thereby offering complementary
information to these previous analyses (2P2IDB is available at
http://2p2idb.cnrs-mrs.fr). We have analyzed the protein/protein
and protein/inhibitor interfaces in terms of geometrical param-
eters, atom and residue properties, buried accessible surface area
and other biophysical parameters, such as the protein-protein
dissociation constant (Kd) of a complex. The interfaces found in
2P2IDB were then compared to those of representative datasets of
heterodimeric complexes from Bahadur and Zacharias [9] or from
the ProtorP parameters (http://www.bioinformatics.sussex.ac.uk/
protorp/ and [10].
The architecture present at the interface generally involves a
globular interacting domain, a single secondary structure element
(alpha-helix or beta strand) of a globular protein, or a short
peptide. Complexes in 2P2IDB present globally the same shape
(planarity or eccentricity) than standard heterodimeric complexes,
but their accessible surface areas are significantly smaller. More
strikingly, no major conformational changes are observed between
the different states of the proteins (bound to the biological partner,
the equivalent free form and the form bound to the small molecule
inhibitor). The interfaces are also more hydrophobic than general
PPIs’ interfaces, with less charged residues and more non-polar
atoms. Moreover, fifty percent of the complexes in the 2P2IDB
dataset possess more hydrogen bonds than typical protein-protein
complexes. A set of key descriptors were identified to distinguish
between PPIs with known inhibitors and representative transient
complexes in the protein databank. Transient protein-protein
complexes are defined as protomers that, in vivo, can exist either on
their own or in complex and also undergo an exchange between
the free and complexed form [11].
A new classification based on these parameters is proposed with
potential aims for the future to identify potential new druggable
PPI targets.
Results and Discussion
Dataset Collection
As our goal was to define structural parameters that guide the
development of PPI disruptors, we only considered those protein
families for which a high resolution three dimensional structure
was available for both the protein/protein and the protein/
inhibitor complexes. Homodimers and covalently bound inhibitors
were not taken into account due to their different behavior. When
available, the best resolution structure of the unbound form of the
proteins or a close homologue was included. The dataset was built
through data mining from the literature and by exhaustive search
of the Protein Data Bank (Figure 1 and Material & methods). The
final dataset was compiled into a relational database (2P2IDB) that
was used to further analyze the general properties of protein/
protein interfaces (PPIs) with a known inhibitor. The 2P2IDB
(http://2p2idb.cnrs-mrs.fr) contains a total of 17 protein/protein
complexes corresponding to 14 families and 56 small molecule
inhibitors bound to the corresponding target (Table 1 and figure 2).
There are a limited number of targets in the 2P2I database at this
stage due to the structural prerequisites that were used. However, it
is inevitable that high throughput structural genomic programs
will generate a high level of data. In addition, the development of
improved methodologies for the development of small molecule
inhibitors will rapidly lead to the discovery and structural char-
acterizationofdisruptorsofnewPPIfamilies.Thesenewtargetsand
theircorrespondingligandswillbe incorporatedintothedatabaseas
they appear in the literature and the Protein Data Bank (http://
www.rcsb.org/).
To assess the characteristics of druggable PPIs, the general
properties of the interfaces found in 2P2IDB were compared
to those of representative datasets of heterodimeric complexes
retrieved from Bahadur and Zacharias [9] and from the ProtorP
server [10].
Global and Local Rearrangements
PPI with known inhibitors do not undergo large
conformational changes. The formation of heterodimeric
complexes can lead to large rearrangements of the two protein
partners [12]. To assess this point, we measured the root mean
square deviation (rmsd) between the bound partners, the
equivalent free forms and the form bound to a small molecule
inhibitor for each complex family (Table 2 and Table S1).
Strikingly, complexes stored in 2P2IDB only underwent minor
local adaptation during complex formation. The average rmsd
(1.1260.4 A ˚) was not significantly different than the natural
conformational dynamics of the free target protein and was in the
same range as the resolution of the crystal structures. Some local
rearrangements could be observed at the binding site; however,
these rearrangements do not impair the possibility to design potent
inhibitors with high affinity. The fact that there is no main
rearrangement between the different forms in the 2P2IDB dataset
could mean that these types of complexes are easier to target.
Other strategies with small molecule inhibitors binding at different
Figure 1. Flow chart indicating how the 2P2IDB dataset was
build from data mining. Two separate approaches were used to
retrieve protein/protein complexes with known inhibitors for which
structural information was available. The protein databank was search
through the Dockground server [23] which led to 202 complexes that
were filtered using an advanced query and manual inspection of the
interface to give 9 protein/protein complexes and 25 protein/inhibitor
complexes. Exhaustive search of the literature led to the discovery of 8
protein complexes corresponding to 31 protein/ligand complexes.
doi:10.1371/journal.pone.0009598.g001
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be necessary to disrupt PPIs with large conformational rearrange-
ments. These classes of inhibitors are not present in the 2P2IDB,a s
we only kept those ligands that are present at the interface.
General Properties of the Interacting Partners
PPI with known inhibitors can be divided into two
classes. We analyzed the general characteristics of the
protein/protein interfaces (PPIs) using online servers [10] or
local visualization programs. The 17 complexes could be divided
into two classes according to the number of continuous segments
at the interface (Tables 1 & 2). Class I contained six of the 17 PPIs
(Table 1, families 1 to 5) and used a limited number of continuous
segments for binding to the partner (average value 3.361.4).
Interestingly, small peptides are able to mimic the interacting
partner for this class of complexes (Table 1, families 1 to 5 and
references therein). The remaining eleven PPIs used a high
number (average value of 8.460.9) and corresponded to actual
globular interacting domains (complex families 6–13 in Table 1).
A more detailed analysis revealed that complexes from class I
contained a higher proportion of secondary structure elements at
the interface. Four out of 6 complexes involved mainly an alpha
helix at the interface, and the other two a beta strand (see
supplementary material, Table S2). Class I PPIs involved a well
ordered partner, which might be easier to mimic with small
molecules. This later observation could account for the greater
number of inhibitors developed for this type of interface [4].
Alternatively, PPIs from class II contained a higher proportion of
nonstructured elements probably due to their larger size. However,
it is noteworthy that the difference in nature of these two sets of PPIs
does not seem to affect the size of the small molecule inhibitors
because similar molecular weight ranges and averages were
observed in our dataset for the two classes (data not shown).
When available, dissociation (KD) or inhibitory (Ki) constants of
the protein/protein complexes were compared (Table 1). On
average, class I complexes corresponded to low affinity complexes
in the micromolar range, whereas class II complexes revealed a
higher affinity in the nano or sub-nanomolar range.
Subsequent analyses were performed on the two classes of
complexes including analysis of the protein/protein and protein/
inhibitor interfaces in terms of geometrical parameters, atom and
residue properties, and buried surface area at the interface.
Geometry of the Interfaces
PPI with known inhibitors are smaller than standard
heterodimers. The size of the interface was computed for each
PPI by measuring the buried surface area between the protein/
protein complexes and the unbound proteins. The average
interface area of 685.26200 A ˚ 2 (ranging linearly from 241 to
947 A ˚ 2) was significantly smaller than the standard average values
of approximately 1000 A ˚ 2 observed for heterodimeric protein-
protein complexes, as described in the literature by Bahadur and
Zacharias [9] and on the ProtorP server [10]. The average values
of 5326198 A ˚ 2 and 7696150 A ˚ 2 were observed for class I
(families 1–5 in Table 1) and class II (family 6–13 in Table 1)
complexes respectively. The average area of the interface is
smaller when the interaction involves a short peptide segment.
Moreover, this analysis also illustrate that interfaces with a known
PPI inhibitor are slightly smaller than overall protein-protein
complexes. However, the 17 interfaces analyzed cover a wide
linear range in terms of size, which indicates that the size of the
interface does not thwart the definition of a potential target.
PPI with known inhibitors share geometrical properties
with heterodimers. The average planarity of interfaces in our
dataset was 2.860.4 A ˚, which is a value equivalent to that of overall
heterodimeric complexes (2.761.2 A ˚). Similarly, eccentricity (i.e., the
Table 1. Complex families in 2P2IDB.
Class # Family Complex
a
Number of
Inhibitors
b Source
c
Affinity
d
(nM) Ref
I 1 BclXL/Bak 1bxl 8 PubMed 340 [27]
I 2 MDM2/p53 1ycr 1ycq 3 PubMed 600 [28]
I 3 XIAP BIR3/CASPASE 9 1nw9 2 PubMed 20 [29]
I 4 XIAP BIR3/SMAC 1g73 5 PubMed 420 [29]
I 5 ZipA/FtsZ 1f47 4 PubMed 20,000 [30]
II 6 Chagasin/Papain 3e1z 1 PDB 0.036
e [31]
II 7 E2/E1 1tue 1 PubMed na [32]
II 8 FKBP12/TGFR 1b6c 17 PDB na [33]
II 9 IL-2/IL-2R 1z92 8 PubMed 10 [34]
II 10 MMP1/TIMP1 2j0t 1 PDB 0.40
e [35]
II 11 MMP3/TIMP1 1oo9 1 PDB 0.22
e [36]
II 12 Subtilisin/Eglin C 1cse 1r0r 1to2 1 PDB 0.029 [37–39]
II 13 Thrombin/Protein C inhibitor 3b9f 1 PDB na [40]
II 14 Trypsin/Trypsin inhibitor 2uuy 3 PDB 0.02 [41]
PPIs were subdivided into class I that correspond to protein/peptide interactions with less than six segments at the interface (families 1–5) and class II that represent
more globular interacting domains with more segments (families 6–14).
aPDB code of protein/protein complexes.
bNumber of inhibitors present in the database for a given protein/protein complex.
cStructures were retrieved through exhaustive search of the protein databank (PDB) or literature data mining (PubMed).
dDissociation constant (KD) of the protein/protein complexes are indicated in nanomolar when available.
eindicates Ki values.
doi:10.1371/journal.pone.0009598.t001
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through the atoms in the interface) was not significantly dis-
tinguishable (0.7260.12 vs. 0.7060.12). Similar values were
observed for the two classes defined above. The Gap volume index
(GVi) provides a measure of the tightness of a protein-protein complex
[13]. The average GVi values for our dataset and general protein-
protein complexes are 2.861.1 and 2.861.4, respectively. On
average, a tighter fit was observed for class I complexes (2.361.7),
which could be due to their smaller size. However, a large variability
was observed between complexes. The surface complementarity
between the two partners was not correlated with the binding affinity,
which could be accounted for by the entopic and desolvation terms of
the binding energy. The chemical nature of the interface plays a more
important role in defining the strength of the interaction.
Figure 2. List of representative small molecule inhibitors for each protein/protein complex in 2P2IDB. Only the inhibitor used to define
the subset of the interface at 4.5 A ˚ around the ligand is shown. For each inhibitor, the name of the protein family, the PDB code of the complex and
the molecular weight of the ligand are indicated.
doi:10.1371/journal.pone.0009598.g002
The 2P2I Database
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9598Overall, these results strongly suggest that PPIs with known
inhibitors share similar shape properties than average transient
protein-protein complexes.
PPIs with known inhibitors posses few pockets at the
interface. PPIs and PPI inhibitor interactions use a greater
number of small pockets than protein-ligand interactions [14]. The
number and size of pockets at the interface for all the targets in
2P2IDB were calculated using Q-SiteFinder [15]. Average values of
1.860.7, 1.660.7 and 1.760.6 pockets corresponding to active
volumes of 3606244 A ˚ 3, 3036160 A ˚ 3 and 247686 A ˚ 3 were
found for the target proteins in their free form, bound to the
inhibitor and bound to their interacting partner, respectively.
Similar values were observed for the two classes of PPIs. In their
original paper, Fuller et al. reported 663 pockets for PPIs with an
average size of 54 A ˚ 3. However, they calculated 99 pockets for
each protein surface and only 10 could be visualized on the Q-
SiteFinder web server. Because only the larger pockets could be
visualized in that study, this limitation could account for the
slightly smaller number of pockets observed in our dataset
compared to those reported in the literature [14]. ZipA was not
included in the general statistics because modulators of ZipA/FtsZ
possess a remarkable way of binding and they do not penetrate the
ZipA surface (supplementary material, Fig. S1). As a consequence,
no pocket was found at the interface for this target.
We then analyzed the protein/protein and protein/inhibitor
interfaces in terms of chemical properties.
Chemical Nature of the Interface
More hydrogen bonds at the interface. Hydrogen bonds
play a key role in the specificity of the interaction between two
proteins. The number of hydrogen bonds per 100 A ˚ 2 of interface
was estimated for the different complexes of the 2P2IDB dataset.
The average number of hydrogen bonds was comparable to that
reported for protein-protein complexes (0.56 vs 0.52, [9]). On
average, PPIs involving a peptide at the interface (class I) possessed
less hydrogen bonds (0.42) than globular PPIs (class II, 0.64).
However, large variations were observed for individual complexes;
the average number of hydrogen bonds per 100 A ˚ 2 varied from
0.05 to 1.1. Fifty percent of the complexes in the 2P2IDB dataset
possessed between 0.69 and 0.83 hydrogen bonds per 100 A ˚ 2 of
Table 2. General interface parameters of PPIs in the 2P2IDB dataset.
PDB
Plan
(A ˚)
a Ecc
b SecS
c
GV
(A ˚ 3)
d
GV_I
(A ˚)
e Hb
f SB
g
ASA
(A ˚ 2)
h
H_ASA
(%)
i
RMSD
(A ˚)
j
Pockets
(A ˚ 3)
l Seg
m
BclXL/Bak 1bxl 3,60 0,75 H/H 2892 1,75 0,05 0 825 45,6 2,3 97 5
MDM2/p53 1ycr 2,99 0,86 H/H 786 0,60 0,34 1 660 54,2 1,9 351 3
MDM2/p53 1ycq 2,14 0,62 H/H 1286 1,38 0,39 1 455 65,7 1,8 215 2
XIAP BIR3/CASPASE 9 1nw9 2,32 0,78 S/S 3567 1,79 0,78 0 241 100,0 2,4 244 2
XIAP BIR3/SMAC 1g73 2,18 0,73 S/S 3500 5,35 0,88 0 472 88,9 2,3 140 3
ZipA/FtsZ 1f47 2,76 0,75 S/H 3503 3,24 0,09 0 541 39,2 0,9 0 5
mean 2,66 0,75 - 2589 2,35 0,42 0,33 532 65,6 1,9 174,5 3.3
standard dev. 0,57 0,08 - 1238 1,70 0,34 0,52 198 24,3 0,6 122,7 1.4
Chagasin/papain 3e1z 3,00 0,89 C/C 4286 2,26 0,53 0 947 55,4 0,4 279 9
E2/E1 1tue 2,59 0,71 H/H 5042 2,86 0,55 3 946 32,6 1,4 202 7
FKBP12/TGFR 1b6c 2,82 0,42 S/H 5457 3,14 0,17 0 869 57,2 0,5 387 8
IL-2/IL-2R 1z92 2,40 0,86 H/C 4431 2,47 0,7 5 898 39,8 1,3 146 8
MMP1/TIMP1 2j0t 2,76 0,55 C/C 5380 4,08 0,83 0 660 48,8 0,5
k 323 7
MMP3/TIMP1 1oo9 3,02 0,78 C/C 5157 2,76 0,24 0 936 39,7 1,2
k 227 9
Subtilisin/Eglin C 1cse 2,67 0,65 C/S 3858 3,01 0,74 0 640 62,6 0,3 282 8
Subtilisin/Eglin C 1r0r 2,54 0,75 C/C 3763 2,99 0,78 0 630 66,3 0,3 230 9
Subtilisin/Eglin C 1to2 3,11 0,61 C/S 3277 2,25 0,74 1 728 66,4 0,3 275 8
Thrombin/Protein C inhibitor 3b9f 3,41 0,81 C/C 5538 4,33 0,72 2 639 38,0 0,6 350 9
Trypsin/trypsin inhibitor 2uuy 2,57 0,73 C/C 3500 3,12 1,09 1 562 70,1 0,7 154 10
mean 2,81 0,71 - 4517 3,02 0,64 1,09 769 52,4 0,7 259,6 8.4
standard dev. 0.30 0.14 - 836 0,67 0,26 1,64 151 13,3 0,4 76,7 0.9
aPlanarity;
beccentricity;
csecondary structure elements at the interface for the target and related partner;
dGap volume;
eGap volume index;
fHydrogen bonds per 100 A ˚2 of interface;
gSalt bridges;
hAccessible surface area buried at the interface of the protein/protein complex;
iAccessible surface area hidden by the inhibitor;
jRoot mean square deviation (CA atoms) between unbound protein and complex;
kwhen unbound protein was not available, rmsd between protein/protein and protein/ligand complexes was computed;
lTotal pocket volume at the interface;
mNumber of interface residue segments. For each parameter the mean and standard deviation are presented.
doi:10.1371/journal.pone.0009598.t002
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hydrogen bonds than typical protein-protein transient complexes
(supplementary material, Fig. S2). Moreover, we analyzed the
portion of the protein-protein interface that is occupied by the
inhibitor in the protein/ligand form and found that for the
majority of the PPIs, a large number of hydrogen bonds where
located in that region.
Less salt bridges at the interface. PPIs with known
inhibitors possess between zero and two salt-bridges, which are
directly located in the region that is disrupted by the ligand
(Table 2). The equivalent number for transient heterodimers could
not be extracted from the literature, but it is very likely to be
higher than the observed value in our dataset. The interaction
between IL-2 and its receptor is an exception, as it contains five
salt bridges with two of them corresponding to the binding site of
the inhibitor. Interestingly, among the eight known inhibitors, six
possess a guanidinium group that mimics a key arginine (Arg36) of
the partner involved in one of the two salt bridges with a glutamic
acid (Glu62) of the target.
Less charged residues at the interface. On average, PPIs
with known inhibitors contain less charged residues at the interface
(18.9613.8%) than standard transient heterodimers (27.0612.5%).
This result indicates that PPIs with known inhibitors are more
hydrophobic than typical heterodimers, which can be correlated to
theobservationthatsmallmoleculePPImodulatorsarehydrophobic
[4]. However, a wide range of situations was observed with
percentage values (from 0 to 46 percent), which confirms that PPIs
with known inhibitors cover a diverse area of chemical space.
Descriptors of the Interface
We used a student’s t-test to compare the main descriptors of
PPIs in our dataset to standard heterodimers in an attempt to
extract the most discriminating parameters that govern the
druggability of a PPI. The number of interfacial segments,
accessible surface area (ASA), Gap volume, hydrogen bonds and
the percentage of charged residues were selected as the key
parameters that typify PPIs with known inhibitors (Figure 3). The
difference between the 2P2IDB dataset and transient heterodimers
for the four selected parameters corresponded to probabilities
higher than 90% confidence according to the t-distribution table of
significance.
PCA analysis. In addition to the five parameters defined
above (ASA, Gap volume, number of segments at the interface,
hydrogen bonds and percentage of charged residues), the combined
pocket volumes at the interface were used in a principal component
analysis (PCA) to separate the 2P2IDB dataset into different families.
Pockets volumes were not incorporated in the t-test study because
statistics were not available to compare to the transient protein-
protein dataset. However, they were used in the PCA analysis
because they are known to play an important role in protein-protein
specific interaction [14]. Out of the six parameters, four
corresponded to geometric descriptors of the interface (ASA, Gap
volume,numberofinterfacialsegmentsandpocketvolume)andtwo
to the chemical nature of the interface (percentage of charged
residues and hydrogen bonds). The influence of each descriptor is
indicated by the direction and length of the corresponding arrows
(Figure 4). All selected parameters have an important contribution
Figure 3. Student t-test allowing the selection of three main discriminating parameters for the PCA analysis. The t-test was calculated
for the whole dataset and for each class (I and II) separately. Dotted lines indicate a threshold of confidence higher than 90% to differentiate 2P2IDB
complexes from transient heterodimers. On the basis of this analysis, ASA, Gap volume, Number of interfacial segments, hydrogen bonds and the
percentage of charged residues were selected for the PCA analysis.
doi:10.1371/journal.pone.0009598.g003
The 2P2I Database
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analytical space (direction of arrows). Three groups were found as a
result of the clustering (Figure 4A). Interestingly, all six complexes
that belong to class I were grouped together (cluster 1, green), which
validates our choice of parameters for the PCA analysis. Subtilisin/
Eglin Cand trypsin/trypsininhibitorformeda second group,mainly
based on ASA and charged residue parameters (cluster 2, pink). The
remainingseven complexesweregroupedina thirdcluster(cluster3,
purple). Parameters characteristic of weak and strong transient
dimers as defined by Nooren and Thornton [11] were incorporated
in a new PCA analysis. The parameters representative of the weak
and strong dimers were grouped with cluster 1 and 3, respectively
(data not shown). Therefore the PCA analysis with the six selected
key parameters of the interface can be used to predict the type of
interaction of the PPI, which can be of particular interest to define
future targets for the discovery of new PPI inhibitors.
A similar PCA analysis was performed with parameters derived
from the subset of the interface that is in direct contact with the
inhibitor in the protein/ligand structure (Figure 4B). The same
descriptors were used as mentioned above. Again, three clusters
were identified; however, the separation between class I and class
II was not as clear as for the whole interface. Two out of six
complexes from class I behaved differently. In the case of the
XIAP/Caspase complex (PDB code: 1nw9) the high number of
hydrogen bonds and the absence of charged residues were
responsible for its different behavior. In the BclXL/Bak complex
(PDB code: 1bxl), the high values for ASA and the number of
segments and low hydrogen bond content led to its classification
next to the FKBP12/TGFR complex (PDB code: 1b6c).
Subtilisin/Eglin C and trypsin/trypsin, which formed a separated
cluster when considering the whole interface, were grouped
together when considering the part of the interface that interacts
with the ligand.
2P2I Web Server Description
A web server was developed to facilitate the access to the data
calculated for the different PPIs. It allows the user to search for
specific complexes using different query procedures based on
families, pdb codes, Uniprot numbers, cluster family or ligand
properties (Figure 5A). For each query, a table is returned giving a
list of PPIs matching the query. For each protein/protein complex,
the cluster number, the family name, the pdb codes of the protein/
protein complex, the unbound partners and the protein/inhibitor
complex, the three letter code of the ligand and its molecular
weight are given. Links to relevant databases and to literature are
also provided. Finally, a data report containing the main analyses
of PPIs can be accessed in different tabs.
An interactive menu allows the user to compare the properties
of a given PPI to the 2P2IDB dataset using the six key descriptors
that were selected for the PCA analyses (Figure 5B). The
parameters should be pre-calculated using online web servers
(ProtorP [10], PDBSum [16] or Q-SiteFinder [15]) and entered on
the 2P2IDB website. Each parameter is compared to the equivalent
parameter in the 2P2IDB dataset and the number of parameters
that are close or very close to 2P2IDB parameters is returned. An
indication of the type of PPI in terms of binding affinity (weak or
strong) is also provided. Finally, individual scores for each
parameter are calculated. Lower values are indicative of
complexes with high potential to become druggable targets
whereas higher scores are likely to correspond to poorly druggable
complexes.
Conclusions
PPIs interfaces have long been considered to be poorly
druggable because of their general properties. However, in the
last few years, a growing number of PPI inhibitors have been
discovered, and some of these inhibitors have even reached the
Figure 4. PCA analysis. Six key parameters were selected to perform the PCA analysis to separate the complexes into different groups: The five
parameters based on the t-test and defined in figure 3 as well as total pocket volume at the interface. A: Analysis on the whole interface. Three
different PPI clusters were defined. Cluster 1 (green) regrouped all complexes from class I corresponding to targets interacting with a peptide.
Subtilisin and trypsin complexes defined cluster 2 (pink). Cluster 3 (purple) regrouped all other protein/protein complexes. B: Same analysis done on
the part of the interface that is 4.5 A ˚ around the ligand. The protein/protein complexes were in three slightly different clusters. Four out of six class I
complexes were grouped together. Subtilisin and trypsin complexes remained very closely associated.
doi:10.1371/journal.pone.0009598.g004
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available drug targets is very limited [18]. Due to their crucial
role in various biological processes and in the dysfunction of cells,
PPIs will probably become the next generation of successful
therapeutics.
To this critical question ‘‘What makes a PPI an attractive target for the
discovery and development of small molecules?’’ we can portray the good
PPI candidates in a few points, which are summarized from
existing published data, as follows: i) The target should be
validated at least biologically (RNAi, knock-out gene etc…) or,
even more importantly, clinically, and the inhibition of the PPI
should not be associated with toxicity; ii) Key residues involved in
the interaction and defining hot spots should be characterized
through mutagenesis analyses, alanine scanning or by server
prediction; iii) Structural information on the PPI complex and/or
unbound forms should be available to accelerate the process;
bridging water molecules should be taken into account when
available and because the best conformation to target for PPI
inhibition is not necessarily the one found in the complex, the
natural conformational dynamics of the target should be
investigated through molecular dynamic simulations [19], normal
mode analysis [20], conformation ensemble predictions [21] or
NMR [22]; iv) Three to five pockets should be available at the
interface in the free form or in the simulated conformations of the
target for a total volume of at least 250 A ˚ 3 [14].
A recent study concluded that small molecule PPI modulators
are larger (average molecular weight .400 Da), more hydropho-
bic (average alogP ,4), with more aromatic rings (,4 in average)
and make fewer hydrogen bonds with the protein than average
drugs [4]. However, a detailed description of the chemical and
topological spaces of protein interfaces that can be disrupted by
small drugs was not available. The present study leads to a better
definition of a potentially successful PPI target.
We have gathered information available for 17 PPIs with known
inhibitors whose three dimensional structural had been charac-
terized. The interfaces were analyzed in terms of geometrical
parameters, shape and chemical properties. The protein/protein
complexes could be divided into two classes according to different
parameters, such as the number of segments at the interface. Class
I PPIs correspond to those that interact with peptide-like partners
and show more secondary structure elements at the interface,
whereas the class II group comprises more globular protein/
protein complexes with more unstructured elements at the
interface.
The different PPIs were further classified by PCA analysis using
descriptors that were selected based on t-test evaluations and
general analyses of the interfaces. Six interfacial parameters were
selected corresponding to ASA, Gap volume, percentage of
charged residues, number of segments, hydrogen bonds and total
volume pockets. Three clusters were defined as a result of the PCA
analysis; cluster 1 corresponded to class I PPIs, while class II PPIs
were subdivided into two clusters.
Analysis of the part of the PPI that corresponds to the region
directly in contact with the inhibitor led to similar results.
However, minor differences could be observed, which suggests
that parameters that define the druggability of a target are
probably different from the parameters that define the chemical
space of PPI inhibitors. The descriptors were selected for their
ability to discriminate between whole PPIs with known inhibitors
and transient dimers; additional parameters would have to be
selected to predict the chemical space of the ligands that are likely
to disrupt a given PPI.
The number of structurally characterized complexes with
known inhibitors is small. Therefore, the chemical space of PPIs
is not completely covered in the 2P2IDB because of the limited
amount of data currently available. However, the definition of
Figure 5. 2P2IDB Server (http://2p2idb.cnrs-mrs.fr). A: Query procedures to retrieve data stored in the database for each PPI. The database can
be searched by family, by PDB codes of the protein/protein complexes, protein/ligand complexes, or unbound proteins, ligand properties or cluster
number. A list of PDB codes or Uniprot numbers is returned as well as links to relevant databases. A detailed report of properties of each PPI is also
provided. B: Interactive menu to compare user defined PPI properties with the 2P2IDB dataset. The user can enter pre-calculated values for the six key
descriptors that were used in the PCA analyses. In return, these parameters are compared to the 2P2IDB dataset and an estimation of the druggability
of the target is proposed.
doi:10.1371/journal.pone.0009598.g005
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come more and more reliable as the number of 3D structures
increases.
The ZipA example, in which the ligand is lying on the protein
surface in an unconventional way (supplementary material, Fig.
S1), highlights the difficulty of defining general parameters for the
druggability of PPI targets. However, we are at an early stage in
the process of defining new relevant PPI targets and, as for HTS
approaches, the goal is to be able to improve the selection of new
PPI targets rather than define all the potential targets.
Further improvements will include incorporating other param-
eters such as available mutation data, known or predicted hot
spots, dynamic behavior of the interface and the development of
new databases dedicated to other types of PPI (such as disordered
interacting segments and PPIs with large domain rearrangements,
which will need specific descriptors).
The results of our study serve to expand current knowledge with
new data and focuses at the interface of protein/protein complexes
with prior structural knowledge. The proposed classification
should lead to a better definition of potentially successful PPI
targets and will accelerate the process of designing new PPI drugs.
As successes in discovering PPI inhibitors accumulate, the
parameters will be refined and the classification scheme updated.
The whole 2P2I dataset was organized as a relational database
and can be accessed through a publicly available web server
(http://2p2idb.cnrs-mrs.fr).
Materials and Methods
Dataset Collection
The hand curated dataset was constructed using two parallel
approaches:
Search from the PDB. The entire PDB was searched using
Dockground server [23] in order to collect protein-protein
complexes. Crystal structures of heteromultimeric complexes
with a resolution of 2.0 A ˚ or lower were retrieved. Disordered
protein and complexes with nucleic acid were discarded. A total of
202 heteromultimeric complexes were obtained.
The whole Protein Data Bank was then searched using an
advanced query for free protein structures corresponding to each
complex bound to small molecule inhibitors (supplementary
material, Fig. S3). We then manually checked that the inhibitor
was present at the interface between the two proteins and not
covalently bounded to the protein. Nine protein/protein and 25
protein/ligand complexes were finally retrieved (Table 1, Sour-
ce=PDB). When available, the unbound proteins were also
included in the database.
Literature data mining. Eight protein/protein and 31
protein/ligand were retrieved by an exhaustive search of the
literature (Table 1, Source=PubMed). IL-2/IL-2R and MDM2/
p53 families were retrieved directly from the work of Pagliaro et al.
[7]. Other complexes (BclXL/Bak, E2/E1, XIAP BIR3/Caspase,
XIAP BIR3/SMAC, ZipA/FtsZ) were not found in the PDB
search either because the interacting partner was a peptide or
because of the x-ray resolution (.2A ˚).
The two lists were combined to form the final dataset,
which can be downloaded at http://2p2idb.cnrs-mrs.fr/dataset/
2P2Idataset.zip. The whole dataset is composed of 17 protein-
protein complexes, 23 unbound proteins and 64 protein-inhibitor
complexes. The PDB IDs are: 1bxl, 1lxl, 1ysi, 1ysn, 2o2m, 1ysg,
2o2n, 2o22 (BclXL/Bak); 1z1m, 1ttv (MDM2/p53); 1tfq, 1tft
(XIAP_BIR3/CASPASE_9); 1f9x (XIAP_BIR3/SMAC); 1oo9
(MMP3/TIMP1) corresponds to solution NMR structures. All
other PDB codes correspond to x-ray structures.
2P2I Database
The protein-protein interaction inhibition relational database
was developed with MySqL. It stores information about the 17
PPIs described in this study. Scripts for interaction with the DB
have been developed in PhP with the software MyAdmin.
Web Server
The 2P2IDB database can be accessed through a web-based user
interface (http://2p2idb.cnrs-mrs.fr). This platform allows users to
query the database to get structural information about interfaces of
stored complexes. The whole database can be searched by protein
family, PDB codes of the free proteins, protein-protein or protein-
ligand complexes, UniProt numbers, ligand three letter codes or
by cluster number.
The user can also provide key parameters calculated from other
web resources to compare the property of a given PPI to the 2P2I
dataset.
Dataset Analysis
Root mean square deviations. The root mean square
deviations (rmsd) between free and bound states of different
proteins were computed over CA atoms using DaliLite server
(http://www.ebi.ac.uk/Tools/dalilite/index.html) and are
summarized into Table S1.
Geometrical parameters. Planarity, eccentricity, secondary
structure in interface, Gap volume, Gap volume index, number of
atoms in interface, % polar atoms in interface, % non polar atoms
in interface, % neutral atoms in interface, number of residues in
interface, % polar residues in interface and % non polar residues
at the interfaces were calculated with the ProtorP server using
default parameters (http://www.bioinformatics.sussex.ac.uk/
protorp/). Continuous interface segment have been defined in
the literature as a stretch of residues that starts and ends with
interface residues and may contain intervening non-interface
residues. While considering the length of the segment, only
interface residues are counted [13,24].
Size of the interface. Accessible surface area (ASA) and
percentage of charged residues were computed with the Naccess
program with a probe radius of 1.4 A ˚. The size of the interface
corresponded to the difference in ASA between the protein
without its partner and in the complex.
Pocket size and volumes. Pockets at the interface were
computed with the Q-SiteFinder server (http://www.bioinformatics.
leeds.ac.uk/qsitefinder) on the protein-protein, protein-inhibitor
complexes and the equivalent free proteins [14]. The homologous
proteins were superimposed and only the pockets that were at least
partly occupied by the inhibitor were retained.
Secondary structures. The percentage of secondary
structure elements in the interface of the target protein and its
partner were calculated with VMD using in house scripts. Four
categories were defined for the overall class of the interface: H:
Alpha Helix .30% and Beta strands ,30%; S: Alpha Helix
,30% and Beta strands .30%; HS: Alpha Helix .30% and Beta
strands .30%; and Coil: Alpha Helix ,30% and Beta strands
,30%;
Hydrogen bonds and salt bridges at the interface.
Hydrogen bonds were computed with the Pymol software
(http://pymol.sourceforge.net/) using a 3.2 A ˚ distance cutoff
between the hydrogen atom and the acceptor atom and were
checked manually.
A salt bridge was considered when an acidic residue (Asp or
Glu) on one side of the interface and a basic residue (Arg, His or
Lys) on the other side were less than 4.0 A ˚ apart. Each putative
The 2P2I Database
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ks.uiuc.edu/Research/vmd/).
Analysis of a subset of the interface. A subset of the
interface was defined by taking into account only atoms around
4.5 A ˚ of the ligand in the protein-inhibitor complexes (see
supplementary material Table S3).
Statistical Analyses and Clustering
T-test. The t-values were calculated as follows:
t~
M2P2I{MRCSB ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var2P2I=n2P2I ðÞ z VarRCSB=nRCSB ðÞ
p
Where Var2P2I and VarRCSB are the variance of parameters in
each group; M2P2I and MRCSB are means of these groups. The
n2P2I and nRCSB are the total number of complexes in each group.
Based on student’s t-distribution table of significance (http://www.
math.unb.ca/,knight/utility/t-table.htm), values higher than
1.34 correspond to probabilities of more than 90% confidence.
On the one hand, if t-value is positive and greater than 1.34, then
the mean of the studied parameter is significantly greater in the
2P2IDB dataset than in the RCSB transient dimers dataset at 90%
or higher confidence level. On the other hand, if the t-value is
negative and less than 21.34, then the mean of the studied
parameter is significantly less in the 2P2IDB dataset than in the
RCSB transient dimers dataset.
PCA. Six parameters (ASA, Number of segments at the
interface, Gap volume, pocket volume, hydrogen-bonds and the
percent of charged residues in interface) were selected for the
multivariate analysis performed according to the principal
component analysis. Data were analyzed with the R software
(http://www.R-project.org) and the ade4 package [25].
Clustering. Clustering of the PPIs into three groups was
performed using the K-mean method [26].
Supporting Information
Figure S1 ZipA protein in complex with IQZ inhibitor (PDB
code 1S1J). The IQZ inhibitor ZipA surface is shown as a stick
representation. (Figure generated with pymol).
Found at: doi:10.1371/journal.pone.0009598.s001 (0.11 MB
PDF)
Figure S2 Hydrogen bonds per 100 A ˚ 2 of accessible surface
area. The X-axis represents the number of hydrogen bonds per
100 A ˚ 2. The Y-axis illustrates the number of complexes present in
2P2IDB having this number of hydrogen bonds (within 60.1), i.e.
y value at x=0.6 indicates that there are 3 complexes having 0.3
to 0.5 hydrogen bonds per 100 A ˚ 2.
Found at: doi:10.1371/journal.pone.0009598.s002 (0.09 MB
PDF)
Figure S3 Advanced query search of the protein databank. This
table lists the different parameters used to parse the protein
databank to search for proteins bound to a small molecule
inhibitor.
Found at: doi:10.1371/journal.pone.0009598.s003 (0.08 MB
PDF)
Table S1 Root mean square deviations for the complexes in
2P2I database. The rms are computed between the unbound
protein and its equivalent in the protein/protein complex; the
unbound protein and its homologous in complex with the
inhibitor; the protein in complex with its partner and the
homologous in complex with the inhibitor. When several
structures are compared, the average is shown. All RMSD were
performed over CA atoms with the DaliLite web server.
Found at: doi:10.1371/journal.pone.0009598.s004 (0.15 MB
PDF)
Table S2 Secondary structure at interface. This table lists
secondary structures at interface (as defined in M&M) for each
complex present in 2P2IDB. Information is detailed for both the
target protein and its partner.
Found at: doi:10.1371/journal.pone.0009598.s005 (0.16 MB
PDF)
Table S3 Geometrical and chemical parameters for the subset of
the interface at 4.5 A ˚ around the inhibitor. The parameters are
detailed for each complex of 2P2IDB and mean and standard
deviations are shown for class I, class II and the whole database.
Found at: doi:10.1371/journal.pone.0009598.s006 (0.16 MB
PDF)
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